Drug intelligence / Profile preview

TSME-1

Development stage: Preclinical
Modality: Peptides
Administration: Oral

Overview

TSME-1 (Trypsin Cleavage Site Mutated Exendin4-cysteine 1) is an orally bioavailable, trypsin-resistant analog of exendin-4, a glucagon-like peptide-1 receptor agonist. It was designed to overcome the limitations of subcutaneous injection for exendin-4 related drugs and improve patient compliance. TSME-1 has demonstrated similar bioactivity to exendin-4 and significantly normalized blood glucose levels in C57BL/6J mice, showing higher availability compared to exendin-4 and exendin4-cysteine. It is being developed as a strong candidate for the future treatment of type 2 diabetes.

Other names: Trypsin Cleavage Site Mutated Exendin4-cysteine 1

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on TSME-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TSME-1.

Explore the full profile